Equities

P3 Health Partners Inc

PIII:NAQ

P3 Health Partners Inc

Actions
Health CareHealth Care Providers
  • Price (USD)0.7249
  • Today's Change0.085 / 13.32%
  • Shares traded651.46k
  • 1 Year change-60.17%
  • Beta--
Data delayed at least 15 minutes, as of May 06 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 18-May-23
  • 15-Feb-24
  • 14-Mar-24
  • 18-Apr-24
  • 02-May-24
Select bar for recommendation details.
Recommendations02-May-24
Buy1
Outperform2
Hold2
Underperform0
Sell0

Share price forecast in USD

The 3 analysts offering 12 month price targets for P3 Health Partners Inc have a median target of 3.00, with a high estimate of 4.50 and a low estimate of 0.90. The median estimate represents a 313.85% increase from the last price of 0.7249.
High520.8%4.50
Med313.9%3.00
Low24.2%0.90

Earnings history & estimates in USD

On Mar 28, 2024, P3 Health Partners Inc reported 4th quarter 2023 losses of -0.22 per share.
The next earnings announcement is expected on May 08, 2024.
Average growth rate+8.17%
P3 Health Partners Inc reported annual 2023 losses of -0.63 per share on Mar 28, 2024.
Average growth rate-1,259.01%
More ▼

Revenue history & estimates in USD

P3 Health Partners Inc had 4th quarter 2023 revenues of 346.86m. This bettered the 302.97m consensus of the 5 analysts covering the company. This was 26.80% above the prior year's 4th quarter results.
Average growth rate+8.46%
P3 Health Partners Inc had revenues for the full year 2023 of 1.27bn. This was 20.66% above the prior year's results.
Average growth rate+42.66%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.